Last update 21 Nov 2024
TGRX-678
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism Bcr-Abl T315I inhibitors(BCR-ABL T315I mutation inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization  Shenzhen TargetRx, Inc.Startup |
Active Organization Shenzhen TargetRx, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Login to view timeline
Related
6
Clinical Trials associated with TGRX-678A Single-arm, Open-label, Multi-center Phase II Study Evaluating Efficacy and Safety of TGRX-678 in CML-AP Patients Relapsed or Refractory From 3rd-generation TKI Treatment
A Single-arm, Open-label, Dose Escalation + Cohort Expansion Phase 1 Trial on Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 in Subjects With Refractory or Advanced Chronic Myelogenous Leukemia
一项评价TGRX-678在慢性粒细胞白血病患者中的安全性、耐受性、药代动力学和初步疗效的单臂、开放、剂量递增、I期临床试验
[Translation] A single-arm, open-label, dose-escalation, Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of TGRX-678 in patients with chronic myeloid leukemia
100 Clinical Results associated with TGRX-678
Login to view more data
100 Translational Medicine associated with TGRX-678
Login to view more data
100 Patents (Medical) associated with TGRX-678
Login to view more data
100 Deals associated with TGRX-678
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Aggressive-Phase Chronic Myelocytic Leukemia | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 05 Jun 2024 |
| Philadelphia chromosome positive chronic myelogenous leukemia | Phase 1 | CN | Shenzhen TargetRx, Inc.Startup | 29 Mar 2021 |
| refractory chronic myelocytic leukemia | Phase 1 | CN | Shenzhen TargetRx, Inc.Startup | 29 Mar 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | - | (mwnpizevzn) = izezvrygzg gyppuculco (xfmxeuyrvb ) View more | - | 08 Dec 2024 | ||
Phase 1 | 95 | (wdbnirfwjk) = lktnvmnuoo yzigwitecz (hitsarcvph ) View more | - | 11 Dec 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free